# US 2023/0068960 A1 · Compositions and methods for treatment of inflammatory and immune diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068960 A1
- Document ID: US20230068960A1
- Status: Published application
- Kind: A1
- Application number: 17/638,137
- Filed: 2020-09-24
- Published: 2023-03-02
- Earliest claimed: 2019-09-24
- Assignees: Prolacta Bioscience, Inc.
- Applicants: Prolacta Bioscience, Inc.
- Inventors: David N. COOK; Gregory MCKENZIE; Julie E. BUTTON
- Web page: https://patentgrep.com/patent/US20230068960A1

## CPC

- A61K 35/745: Bifidobacteria
- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/38: Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N1/34 takes precedence)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are compositions, methods, strategies, kits, and articles of manufacture that are useful, inter alia, in the treatment or prevention of diseases or conditions such as those which may be associated with inflammation, infection, allergy, immune dysfunction, or dysbiosis of the intestinal microbiome. In some aspects, the invention provides a synergistic combination of a prebiotics, e.g., a mixture of human milk oligosaccharides, and a probiotic strain, such as a strain capable of internalizing and consuming the rebiotics, e.g., B. longum subsp. infantis.

## Claims

### Claim 1

A method for treating or preventing a disease, disorder, or condition associated with one or more of dysbiosis of the intestinal microbiome, inflammation, infection, allergy, or immune dysfunction in a subject in need thereof, the method comprising administering to the subject (i) a prebiotic mixture comprising one or more human milk oligosaccharides and (ii) at least one probiotic strain of bacterium comprising B. longum subsp. infantis, B. longum subsp. longum, B. breve, or B. bifidum.

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the probiotic strain of bacterium comprises B. longum subsp. infantis.

### Claim at position 4

6-8. (canceled)

### Claim 9 (depends on 1)

The method claim 1, wherein the disease, disorder, or condition comprises one or more of obesity, type II diabetes, a chronic inflammatory disease, an autoimmune disease, an infection, an infectious disease domination, bowel resection, or a condition associated with chronic diarrhea.

### Claim 10 (depends on 1)

The method of claim 1, wherein the disease, disorder, or condition comprises one or more of irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), short bowel syndrome (SBS), celiac disease, small intestinal bacterial overgrowth (SIBO), gastroenteritis, leaky gut syndrome, pouchitis, or gastric lymphoma.

### Claim 11 (depends on 1)

The method of claim 1, wherein the disease, condition, or disorder is graft versus host disease.

### Claim at position 8

12-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the disease, condition, or disorder comprises a bacterial infection or gut domination.

### Claim at position 10

15-16. (canceled)

### Claim 17 (depends on 14)

The method of claim 14, wherein the bacterial infection or gut domination comprises an infection or gut domination by one or more species, subspecies, or strains of Aeromonas, Bacillus, Blautia, Bordetella, Borrelia, Brucella, Burkholderia, Campylobacter, Chlamydia, Chlamydophila, Citrobacter, Clostridium, Corynebacterium, Coxiella, Ehrlichia, Enterobacter, Enterobacteriaceae, Enterococcus, Escherichia, Faecalicatena, Francisella, Haemophilus, Helicobacter, Hungatella, Klebsiella, Lachnospiraceae, Legionella, Leptospira, Listeria, Morganella, Mycobacterium, Mycoplasma, Neisseria, Orientia, Plesiomonas, Proteus, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Vibrio, or Yersinia, optionally one or more of Aeromonas hydrophila, Bacillus cereus, Campylobacter fetus, Campylobacter jejuni, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, enteroaggregative Escherichia coli, enterohemorrhagic Escherichia coli, enteroinvasive Escherichia coli, enteropathogenic E. coli, enterotoxigenic Escherichia coli, Escherichia coli 0157:H7, Helicobacter pylori, Klebsiellia pneumonia, Lysteria monocytogenes, Salmonella paratyphi, Salmonella typhi, Staphylococcus aureus, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus, or Yersinia enterocolitica.

### Claim 18

(canceled)

### Claim 19 (depends on 14)

The method of claim 14, wherein the bacterial infection or gut domination comprises an infection or gut domination by drug-resistant bacteria comprising one or more of antibiotic-resistant bacterium (ARB), Antibiotic-resistant Proteobacteria, Carbapenem-resistant Enterobacteriaceae (CRE), Extended Spectrum Beta-Lactamase producing Enterobacteriaceae (ESBL-E), fluoroquinolone-resistant Enterobacteriaceae, extended spectrum beta-lactam resistant Enterococci (ESBL), vancomycin-resistant Enterococci (VRE), multi-drug resistant E. coli, or multi-drug resistant Klebsiella.

### Claim at position 14

20-22. (canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein the prebiotic mixture comprises at least 10 human milk oligosaccharides.

### Claim 24 (depends on 1)

The method of claim 1, wherein the prebiotic mixture comprises at least 25 human milk oligosaccharides.

### Claim 25 (depends on 1)

The method of claim 1, wherein the prebiotic mixture comprises at least 50 human milk oligosaccharides.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The method of claim 1, wherein the prebiotic mixture comprises one or more of 2′-fucosyl-lactose, 3′-fucosyl-lactose, 3′-sialyl-lactose, 6′-sialyl-lactose, Lacto-N-tetraose, lacto-N-difucohexaose I, lactodifucotetraose, Lacto-N-fucopentaose I, sialylacto-N-tetraose c, sialylacto-N-tetraose b, or disialyllacto-N-tetraose.

### Claim at position 20

28-29. (canceled)

### Claim 30 (depends on 1)

The method of claim 1, wherein the prebiotic mixture is, is derived from, or comprises a concentrated permeate from pooled human milk, wherein the permeate is obtained from the ultrafiltration of human skim milk, wherein the human skim milk is obtained by removing cream from pooled human milk, and wherein the pooled human milk is pooled from the milk of multiple human milk donors.

### Claim at position 22

31-33. (canceled)

### Claim 34 (depends on 1)

The method of claim 1, wherein the prebiotic mixture and the probiotic strain are administered orally.

### Claim at position 24

35-37. (canceled)

### Claim 38 (depends on 1)

The method of claim 1, wherein the method comprises at least a first treatment phase and a second treatment phase, wherein the first treatment phase comprises administering to the subject the prebiotic mixture and the probiotic strain on the same day for at least one day, and wherein the second treatment phase begins after the end of the first treatment phase, optionally immediately after, and comprises administering the prebiotic mixture for at least one day, wherein the probiotic strain is not administered during the second treatment phase.

### Claim at position 26

39-40. (canceled)

### Claim 41 (depends on 1)

The method of claim 1, wherein the first treatment phase is between 3 and 14 days in length and wherein the second treatment phase is between 3 and 14 days in length.

### Claim 42

(canceled)

### Claim 43 (depends on 1)

The method of claim 1, wherein the probiotic strain is administered in an amount of at least 5×106 colony forming units (CFU) per day.

### Claim 44

(canceled)

### Claim 45 (depends on 1)

The method of claim 1, wherein the prebiotic mixture is administered in an amount of at least 500 mg of total human milk oligosaccharides per day.

### Claim 46 (depends on 45)

The method of claim 45, wherein the prebiotic mixture is administered in an amount of between 0.5 g and 25 g, 1 g and 5 g, 2 g and 3 g,3 g and 6 g, 4 g and 5 g, 5 g and 10 g, 8 g and 10 g, 10 g and 20 g, 15 g and 25 g, 15 g and 20 g, or 17 g and 19 g of total human milk oligosaccharides per day.

### Claim at position 33

47-53. (canceled)

### Claim 54 (depends on 1)

The method of claim 1, wherein the subject is a human subject that is a child, an adolescent, or an adult.

### Claim at position 35

55-86. (canceled)

### Claim 87

A method of reducing ammonia in a subject in need thereof, comprising administering to a subject (i) a prebiotic mixture of oligosaccharides, wherein all or essentially all of the oligosaccharides of the prebiotic mixture are human milk oligosaccharides (HMOs) that do not incorporate an N-acetyl glucosamine residue, and (ii) a probiotic strain of bacterium, wherein the probiotic strain of bacterium comprises B. longum subsp. infantis.

### Claim at position 37

88-98. (canceled)
